[
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific (TMO) Unveils Next-Day Genomic Profiling With Oncomine Assay Plus",
    "summary": "Thermo Fisher Scientific (TMO) recently introduced the Oncomine Comprehensive Assay Plus, advancing its genomic profiling solutions, which may have bolstered its stock's 6% increase over the past month. This technological enhancement provides next-day results, crucial in oncological research. Meanwhile, broader markets remained flat, with inflation data affecting investor sentiment. However, Thermo Fisher's growth was supported by an FDA approval for a cancer diagnostic tool and a substantial...",
    "url": "https://finnhub.io/api/news?id=5a368d09c63bd8934703c252b63c09b964db09fdf24b784f74456bfa634a4644",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752600690,
      "headline": "Thermo Fisher Scientific (TMO) Unveils Next-Day Genomic Profiling With Oncomine Assay Plus",
      "id": 135961507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific (TMO) recently introduced the Oncomine Comprehensive Assay Plus, advancing its genomic profiling solutions, which may have bolstered its stock's 6% increase over the past month. This technological enhancement provides next-day results, crucial in oncological research. Meanwhile, broader markets remained flat, with inflation data affecting investor sentiment. However, Thermo Fisher's growth was supported by an FDA approval for a cancer diagnostic tool and a substantial...",
      "url": "https://finnhub.io/api/news?id=5a368d09c63bd8934703c252b63c09b964db09fdf24b784f74456bfa634a4644"
    }
  },
  {
    "ts": null,
    "headline": "XPH: Healthcare Dashboard For July",
    "summary": "XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade. Click here to find out why XPH stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=f06d8fa42a12451bc189fb589853168778c65a1452470f7473adbf64804e67f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752599588,
      "headline": "XPH: Healthcare Dashboard For July",
      "id": 135956660,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1557045133/image_1557045133.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "XPH ETF offers equal-weighted exposure to pharmaceutical companies, with lackluster results for a decade. Click here to find out why XPH stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=f06d8fa42a12451bc189fb589853168778c65a1452470f7473adbf64804e67f9"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market",
    "summary": "Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market",
    "url": "https://finnhub.io/api/news?id=9701cc3962422427bd72e3252822d7953a6dba6dd7baef96a7123ea0baab3b9d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752597300,
      "headline": "Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market",
      "id": 135976796,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market",
      "url": "https://finnhub.io/api/news?id=9701cc3962422427bd72e3252822d7953a6dba6dd7baef96a7123ea0baab3b9d"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4",
    "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL). Under the terms of the agreement, Thermo Fisher is to become the Contract Development and Manufacturing Organization (CDMO) for AD04 Drug products. The product is […]",
    "url": "https://finnhub.io/api/news?id=e6cf5e5a7b2834fa8dd2ff3ebe9d37ea8d49c53e5cae1f4a398c60c4a8cdc594",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752585038,
      "headline": "Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4",
      "id": 135961508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL). Under the terms of the agreement, Thermo Fisher is to become the Contract Development and Manufacturing Organization (CDMO) for AD04 Drug products. The product is […]",
      "url": "https://finnhub.io/api/news?id=e6cf5e5a7b2834fa8dd2ff3ebe9d37ea8d49c53e5cae1f4a398c60c4a8cdc594"
    }
  },
  {
    "ts": null,
    "headline": "Is Thermo Fisher Scientific Inc.'s (NYSE:TMO) Recent Stock Performance Influenced By Its Fundamentals In Any Way?",
    "summary": "Thermo Fisher Scientific's (NYSE:TMO) stock is up by a considerable 5.6% over the past month. Given that stock prices...",
    "url": "https://finnhub.io/api/news?id=b18c23b7db47cbd95626e6611908ba4cf997ccdc399458789648aab2067d023b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752577213,
      "headline": "Is Thermo Fisher Scientific Inc.'s (NYSE:TMO) Recent Stock Performance Influenced By Its Fundamentals In Any Way?",
      "id": 135961510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific's (NYSE:TMO) stock is up by a considerable 5.6% over the past month. Given that stock prices...",
      "url": "https://finnhub.io/api/news?id=b18c23b7db47cbd95626e6611908ba4cf997ccdc399458789648aab2067d023b"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner Global Equity Q2 2025 Report",
    "summary": "The Global Equity composite rose 10.3% gross of fees in the second quarter, lagging the 11.7% gain in the MSCI ACWI Index.",
    "url": "https://finnhub.io/api/news?id=8ec65fb5791a8926881b2ee37698c3f7289d7fd8997db8809c0e93fef327274b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752573600,
      "headline": "Harding Loevner Global Equity Q2 2025 Report",
      "id": 135945766,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2067714497/image_2067714497.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "The Global Equity composite rose 10.3% gross of fees in the second quarter, lagging the 11.7% gain in the MSCI ACWI Index.",
      "url": "https://finnhub.io/api/news?id=8ec65fb5791a8926881b2ee37698c3f7289d7fd8997db8809c0e93fef327274b"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Value Equity Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752569820,
      "headline": "Parnassus Value Equity Fund Q2 2025 Commentary",
      "id": 135943720,
      "image": "",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8da32aa99f91d77430a6333e00c9076e612b9dbc7e69491bd5ddc74be3c14dc2"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Growth Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Growth Equity Fund (Investor Shares) returned 18.97% (net of fees) during the quarter, outperforming the Russell 1000 Growth Indexâs 17.84%. Read more here.",
    "url": "https://finnhub.io/api/news?id=76cb4babf97141731cff29a2d4e1fa66167489bdd2866cdffbd4540e8483e33e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752567720,
      "headline": "Parnassus Growth Equity Fund Q2 2025 Commentary",
      "id": 135943109,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182036952/image_2182036952.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Parnassus Growth Equity Fund (Investor Shares) returned 18.97% (net of fees) during the quarter, outperforming the Russell 1000 Growth Indexâs 17.84%. Read more here.",
      "url": "https://finnhub.io/api/news?id=76cb4babf97141731cff29a2d4e1fa66167489bdd2866cdffbd4540e8483e33e"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Core Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Core Equity Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=7f21b46d510fc34a6ca2316565655fc51487440827c8a003d40c5ac7d653cd0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752566520,
      "headline": "Parnassus Core Equity Fund Q2 2025 Commentary",
      "id": 135942651,
      "image": "",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7f21b46d510fc34a6ca2316565655fc51487440827c8a003d40c5ac7d653cd0c"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Value Select ETF Q2 2025 Commentary",
    "summary": "Parnassus Value Select ETF returned 6.38% (net of fees) for the quarter, outperforming the Russell 1000 Value Indexâs 3.79%. Read more here.",
    "url": "https://finnhub.io/api/news?id=887fa1fb52e2f86d27202dd5cd4ecc464bf49989b2ee52d157dc6864ed4a4a14",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752564480,
      "headline": "Parnassus Value Select ETF Q2 2025 Commentary",
      "id": 135941970,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2220503680/image_2220503680.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Parnassus Value Select ETF returned 6.38% (net of fees) for the quarter, outperforming the Russell 1000 Value Indexâs 3.79%. Read more here.",
      "url": "https://finnhub.io/api/news?id=887fa1fb52e2f86d27202dd5cd4ecc464bf49989b2ee52d157dc6864ed4a4a14"
    }
  }
]